Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFPOUC)

Drug Name
CGP-57380 Drug Info
Synonyms
CGP 57380; 522629-08-9; CGP-57380; MNK1 Inhibitor; N3-(4-fluorophenyl)-1h-pyrazolo[3,4-d]pyrimidine-3,4-diamine; CGP57380; CHEMBL1240885; C11H9FN6; 4-Amino-5-(4-fluoroanilino)-pyrazolo[3,4-d]pyrimidine; SCHEMBL987991; GTPL6010; CHEMBL576817; SCHEMBL16714452; CHEBI:92749; DTXSID50469941; MolPort-006-725-822; HMS3653G22; HMS3269P13; HMS3263L14; HMS3229K20; HMS3648M14; Tox21_501256; BDBM50130693; 2314AH; NSC741567; MFCD03861062; ZINC13816313; s7421; IN1236; BDBM50298223; AKOS024457265; CCG-206868; NSC-741567; LP01256; NCGC00162380-06
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11644425
ChEBI ID
CHEBI:92749
CAS Number
CAS 522629-08-9
TTD Drug ID
DMFPOUC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting LCK tyrosine protein kinase (LCK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Chronic myelogenous leukaemia 2A20.0 Approved [3]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
JNJ-26483327 DMSQ3AZ Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [2]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [5]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [5]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [6]
CI-1040 DMF3DZX Discovery agent N.A. Investigative [5]
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [7]
BMS-536924 DMXJB4N Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Serine/threonine-protein kinase Sgk1 (SGK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RO-316233 DMAGLPW Discovery agent N.A. Investigative [5]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [5]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [6]
CI-1040 DMF3DZX Discovery agent N.A. Investigative [5]
KN-62 DMLZ89P Discovery agent N.A. Investigative [5]
GSK-650394 DMNRP2L Prostate cancer 2C82.0 Investigative [9]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Targeting Aurora B messenger RNA (AURKB mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [10]
Indirubin-3'-monoxime DMLRQH0 Discovery agent N.A. Investigative [11]
SU 6656 DMF1P6W Discovery agent N.A. Investigative [2]
6-bromoindirubin-3-oxime DM12WYV Discovery agent N.A. Investigative [11]
7-fluoroindirubin-3-oxime DMQD34N Discovery agent N.A. Investigative [11]
PMID21742770C1 DME3JMH Discovery agent N.A. Investigative [12]
Indirubin-3-acetoxime DM3UR1E Discovery agent N.A. Investigative [11]
PMID20855207C25 DMNEB6J Discovery agent N.A. Investigative [13]
Indirubin-3-methoxime DMZ5ODC Discovery agent N.A. Investigative [11]
4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine DM9MPHF Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aurora B messenger RNA (AURKB mRNA) TT9RTBL AURKB_HUMAN Inhibitor [2]
LCK tyrosine protein kinase (LCK) TT860QF LCK_HUMAN Inhibitor [2]
Serine/threonine-protein kinase Sgk1 (SGK1) TTTV8EJ SGK1_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6010).
2 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
3 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
4 National Cancer Institute Drug Dictionary (drug id 596693).
5 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
6 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
7 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
8 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8040).
10 Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4.
11 An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
12 A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
13 Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43.
14 Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5.